Literature DB >> 19756211

Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues.

Philip W Lavori1, C Hendricks Brown, Naihua Duan, Robert D Gibbons, Joel Greenhouse.   

Abstract

Entities:  

Year:  2008        PMID： 19756211      PMCID： PMC2743339          DOI： 10.3928/00485713-20081201-04

Source DB:  PubMed          Journal:  Psychiatr Ann        ISSN： 0048-5713


× No keyword cloud information.
  16 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  A mixed-effects multinomial logistic regression model.

Authors:  Donald Hedeker
Journal:  Stat Med       Date:  2003-05-15       Impact factor: 2.373

3.  A case study on the choice, interpretation and checking of multilevel models for longitudinal binary outcomes.

Authors:  J B Carlin; R Wolfe; C H Brown; A Gelman
Journal:  Biostatistics       Date:  2001-12       Impact factor: 5.899

4.  Analyzing incomplete longitudinal clinical trial data.

Authors:  Geert Molenberghs; Herbert Thijs; Ivy Jansen; Caroline Beunckens; Michael G Kenward; Craig Mallinckrodt; Raymond J Carroll
Journal:  Biostatistics       Date:  2004-07       Impact factor: 5.899

5.  The efficiency of two-phase designs in prevalence surveys of mental disorders.

Authors:  S C Newman; P E Shrout; R C Bland
Journal:  Psychol Med       Date:  1990-02       Impact factor: 7.723

6.  The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.

Authors:  Donald B Rubin
Journal:  Stat Med       Date:  2007-01-15       Impact factor: 2.373

7.  Methods for testing theory and evaluating impact in randomized field trials: intent-to-treat analyses for integrating the perspectives of person, place, and time.

Authors:  C Hendricks Brown; Wei Wang; Sheppard G Kellam; Bengt O Muthén; Hanno Petras; Peter Toyinbo; Jeanne Poduska; Nicholas Ialongo; Peter A Wyman; Patricia Chamberlain; Zili Sloboda; David P MacKinnon; Amy Windham
Journal:  Drug Alcohol Depend       Date:  2008-01-22       Impact factor: 4.492

Review 8.  Clinical trials in psychiatry: should protocol deviation censor patient data?

Authors:  P W Lavori
Journal:  Neuropsychopharmacology       Date:  1992-01       Impact factor: 7.853

9.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

10.  Missing Data in Longitudinal Trials - Part B, Analytic Issues.

Authors:  Juned Siddique; C Hendricks Brown; Donald Hedeker; Naihua Duan; Robert D Gibbons; Jeanne Miranda; Philip W Lavori
Journal:  Psychiatr Ann       Date:  2008-12-01
View more
  12 in total

1.  A pharmacogenetic study of escitalopram in autism spectrum disorders.

Authors:  Thomas Owley; Camille W Brune; Jeff Salt; Laura Walton; Steve Guter; Nelson Ayuyao; Robert D Gibbons; Bennett L Leventhal; Edwin H Cook
Journal:  Autism Res       Date:  2010-02       Impact factor: 5.216

2.  Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.

Authors:  Robert D Gibbons; Kwan Hur; C Hendricks Brown; John M Davis; J John Mann
Journal:  Arch Gen Psychiatry       Date:  2012-06

3.  The design and conduct of clinical trials to limit missing data.

Authors:  R J Little; M L Cohen; K Dickersin; S S Emerson; J T Farrar; J D Neaton; W Shih; J P Siegel; H Stern
Journal:  Stat Med       Date:  2012-07-25       Impact factor: 2.373

4.  Missing Data in Longitudinal Trials - Part B, Analytic Issues.

Authors:  Juned Siddique; C Hendricks Brown; Donald Hedeker; Naihua Duan; Robert D Gibbons; Jeanne Miranda; Philip W Lavori
Journal:  Psychiatr Ann       Date:  2008-12-01

5.  Advances in analysis of longitudinal data.

Authors:  Robert D Gibbons; Donald Hedeker; Stephen DuToit
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

6.  Addressing Methodologic Challenges and Minimizing Threats to Validity in Synthesizing Findings from Individual-Level Data Across Longitudinal Randomized Trials.

Authors:  Ahnalee Brincks; Samantha Montag; George W Howe; Shi Huang; Juned Siddique; Soyeon Ahn; Irwin N Sandler; Hilda Pantin; C Hendricks Brown
Journal:  Prev Sci       Date:  2018-02

Review 7.  Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.

Authors:  Kathleen M Carroll; Brian D Kiluk; Charla Nich; Elise E DeVito; Suzanne Decker; Donna LaPaglia; Dianne Duffey; Theresa A Babuscio; Samuel A Ball
Journal:  Drug Alcohol Depend       Date:  2014-01-31       Impact factor: 4.492

Review 8.  Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

Authors:  Brian D Kiluk; Kathleen M Carroll; Amy Duhig; Daniel E Falk; Kyle Kampman; Shengan Lai; Raye Z Litten; David J McCann; Ivan D Montoya; Kenzie L Preston; Phil Skolnick; Constance Weisner; George Woody; Redonna Chandler; Michael J Detke; Kelly Dunn; Robert H Dworkin; Joanne Fertig; Jennifer Gewandter; F Gerard Moeller; Tatiana Ramey; Megan Ryan; Kenneth Silverman; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2015-11-21       Impact factor: 4.492

Review 9.  Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Treat Options Oncol       Date:  2014-12

10.  Methodological Considerations for Advancing Research on the Health and Wellbeing of Sexual and Gender Minority Youth.

Authors:  Sheree M Schrager; Riley J Steiner; Alida M Bouris; Kathryn Macapagal; C Hendricks Brown
Journal:  LGBT Health       Date:  2019 May-Jun       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.